Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects

Simon Pernot; Cecile Badoual; Magali Terme; Florence Castan; Aurelie Cazes; Olivier Bouche; Jaafar Bennouna; Eric Francois; Francois Ghiringhelli; Christelle De La Fouchardiere; Emmanuelle Samalin; Jean Baptiste Bachet; Christophe Borg; Michel Ducreux; Elie Marcheteau; Trevor Stanbury; Sophie Gourgou; David Malka; Julien Taieb

doi:10.1016/j.ejca.2017.03.036

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects

Simon Pernot
, Cecile Badoual
, Magali Terme
, Florence Castan
, Aurelie Cazes
, Olivier Bouche
, Jaafar Bennouna
, Eric Francois
, Francois Ghiringhelli
, Christelle De La Fouchardiere
, Emmanuelle Samalin
, Jean Baptiste Bachet
, Christophe Borg
, Michel Ducreux
, Elie Marcheteau
, Trevor Stanbury
, Sophie Gourgou
, David Malka
, Julien Taieb

Descartes University e INSERM U 970
Assistance publique – Hôpitaux de Paris
Centre régional de lutte du cancer Val d'Aurelle
Hôpital Robert Debré, CHU de Reims
Institut de Cancérologie de l'Ouest
Centre Antoine Lacassagne
Centre Georges-François Leclerc
Centre Léon Bérard
Sorbonne Université
Hôpital Jean Minjoz
Institut Gustave Roussy
Unicancer

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Abstract

Background The identification of dynamic biomarkers in advanced gastric and oesogastric junction adenocarcinoma (GOA) could help to tailor strategies for each patient. Enumeration of circulating tumour cells (CTCs) is approved by the US Food and Drug Administration in breast, colon and prostate cancer but is not in advanced GOA. Our study aims to establish the optimal threshold and the clinical significance of CTC count in advanced GOA before and during treatment. Methods One hundred six patients with untreated advanced GOA were included in the ancillary study of the PRODIGE 17-ACCORD 20 trial. CTCs were detected in the peripheral blood using the CellSearch system on day 0 (D0) and day 28 (D28). The prognostic value of CTCs at D0 and D28 was analysed by testing several thresholds. Results At baseline, median CTC count was 1 (range, 0–415). While CTCs ≥1, 2 or 3 at D0 were all significantly associated with worse overall survival (OS) and progression-free survival (PFS), CTCs ≥2 were the optimal threshold, on D0 or D28. CTCs ≥2 at D28 were also predictive of disease control. Taking into account both D0 and D28 CTC count defined 3 groups (low/low, high/low and low-high/high) with significantly different PFS (p = 0.0002) and OS (p = 0.003). Conclusion Quantification of CTCs at baseline and during treatment may be a useful prognostic tool in advanced GOA, as it is associated with worse PFS and OS. A threshold ≥2 CTCs seems to have the best discriminant value. Change in CTC count between baseline and D28 could help to tailor treatment to each individual patient.

Original language	English
Pages (from-to)	15-22
Number of pages	8
Journal	European Journal of Cancer
Volume	79
DOIs	https://doi.org/10.1016/j.ejca.2017.03.036
State	Published - 1 Jul 2017
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2017 Elsevier Ltd

Funding

Dr. Pernot reports grants from Amgen, non-financial support from Veridex, non-financial support from Johnson & Johnson, during the conduct of the study; personal fees and non-financial support from Amgen, non-financial support from Merck, personal fees and non-financial support from Sanofi, personal fees from BTG, outside the submitted work; Dr. Ducreux reports personal fees from Amgen, grants and personal fees from Merck, personal fees from Sanofi, grants and personal fees from Roche, personal fees from Novartis, personal fees from Bayer, personal fees from Sirtex, personal fees from Lilly, personal fees from Servier, personal fees from Terumo, grants from Pfizer, outside the submitted work; Dr. de la Fouchardiere reports personal fees and non-financial support from Lilly, outside the submitted work; Dr. Bennouna reports personal fees from Boerhinger Ingelheim, personal fees from Roche, personal fees from Astrazeneca, personal fees from MSD, personal fees from BMS, outside the submitted work; Dr. Ghiringhelli reports personal fees from Amgen, outside the submitted work; Dr. Bouche reports personal fees from Roche, personal fees from Merck, personal fees from Novartis, personal fees from Lilly, personal fees from Boehringer, outside the submitted work; Dr. Terme reports personal fees from Roche, outside the submitted work; Dr. Bachet reports personal fees from Amgen, personal fees from Merck, personal fees from Roche, personal fees from Sanofi, personal fees from Bayer, personal fees from Cellgene, personal fees from Lilly, outside the submitted work; Dr. Borg reports personal fees from Roche, personal fees from Bayer, personal fees from Lilly, outside the submitted work; Dr. Taieb reports personal fees and non-financial support from Amgen, personal fees and non-financial support from Merck, personal fees and non-financial support from Roche, personal fees from Sanofi, personal fees from Lilly, personal fees from BTG, personal fees from Sirtex, outside the submitted work. All remaining authors have declared no conflicts of interest.

Funders
Amgen
Johnson and Johnson
Merck
Roche

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Biomarkers
Circulating tumour cells
Clinical trial
Prognosis
Stomach neoplasms

Access to Document

10.1016/j.ejca.2017.03.036

Cite this

Pernot, S., Badoual, C., Terme, M., Castan, F., Cazes, A., Bouche, O., Bennouna, J., Francois, E., Ghiringhelli, F., De La Fouchardiere, C., Samalin, E., Bachet, J. B., Borg, C., Ducreux, M., Marcheteau, E., Stanbury, T., Gourgou, S., Malka, D., & Taieb, J. (2017). Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. European Journal of Cancer, 79, 15-22. https://doi.org/10.1016/j.ejca.2017.03.036

@article{be1e7b8899f14c05b4a948d4313a03b3,

title = "Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects",

abstract = "Background The identification of dynamic biomarkers in advanced gastric and oesogastric junction adenocarcinoma (GOA) could help to tailor strategies for each patient. Enumeration of circulating tumour cells (CTCs) is approved by the US Food and Drug Administration in breast, colon and prostate cancer but is not in advanced GOA. Our study aims to establish the optimal threshold and the clinical significance of CTC count in advanced GOA before and during treatment. Methods One hundred six patients with untreated advanced GOA were included in the ancillary study of the PRODIGE 17-ACCORD 20 trial. CTCs were detected in the peripheral blood using the CellSearch system on day 0 (D0) and day 28 (D28). The prognostic value of CTCs at D0 and D28 was analysed by testing several thresholds. Results At baseline, median CTC count was 1 (range, 0–415). While CTCs ≥1, 2 or 3 at D0 were all significantly associated with worse overall survival (OS) and progression-free survival (PFS), CTCs ≥2 were the optimal threshold, on D0 or D28. CTCs ≥2 at D28 were also predictive of disease control. Taking into account both D0 and D28 CTC count defined 3 groups (low/low, high/low and low-high/high) with significantly different PFS (p = 0.0002) and OS (p = 0.003). Conclusion Quantification of CTCs at baseline and during treatment may be a useful prognostic tool in advanced GOA, as it is associated with worse PFS and OS. A threshold ≥2 CTCs seems to have the best discriminant value. Change in CTC count between baseline and D28 could help to tailor treatment to each individual patient.",

keywords = "Biomarkers, Circulating tumour cells, Clinical trial, Prognosis, Stomach neoplasms",

author = "Simon Pernot and Cecile Badoual and Magali Terme and Florence Castan and Aurelie Cazes and Olivier Bouche and Jaafar Bennouna and Eric Francois and Francois Ghiringhelli and \{De La Fouchardiere\}, Christelle and Emmanuelle Samalin and Bachet, \{Jean Baptiste\} and Christophe Borg and Michel Ducreux and Elie Marcheteau and Trevor Stanbury and Sophie Gourgou and David Malka and Julien Taieb",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Ltd",

year = "2017",

month = jul,

day = "1",

doi = "10.1016/j.ejca.2017.03.036",

language = "אנגלית",

volume = "79",

pages = "15--22",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

Pernot, S, Badoual, C, Terme, M, Castan, F, Cazes, A, Bouche, O, Bennouna, J, Francois, E, Ghiringhelli, F, De La Fouchardiere, C, Samalin, E, Bachet, JB, Borg, C, Ducreux, M, Marcheteau, E, Stanbury, T, Gourgou, S, Malka, D & Taieb, J 2017, 'Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects', European Journal of Cancer, vol. 79, pp. 15-22. https://doi.org/10.1016/j.ejca.2017.03.036

TY - JOUR

T1 - Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma

T2 - Prognostic value and early assessment of therapeutic effects

AU - Pernot, Simon

AU - Badoual, Cecile

AU - Terme, Magali

AU - Castan, Florence

AU - Cazes, Aurelie

AU - Bouche, Olivier

AU - Bennouna, Jaafar

AU - Francois, Eric

AU - Ghiringhelli, Francois

AU - De La Fouchardiere, Christelle

AU - Samalin, Emmanuelle

AU - Bachet, Jean Baptiste

AU - Borg, Christophe

AU - Ducreux, Michel

AU - Marcheteau, Elie

AU - Stanbury, Trevor

AU - Gourgou, Sophie

AU - Malka, David

AU - Taieb, Julien

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background The identification of dynamic biomarkers in advanced gastric and oesogastric junction adenocarcinoma (GOA) could help to tailor strategies for each patient. Enumeration of circulating tumour cells (CTCs) is approved by the US Food and Drug Administration in breast, colon and prostate cancer but is not in advanced GOA. Our study aims to establish the optimal threshold and the clinical significance of CTC count in advanced GOA before and during treatment. Methods One hundred six patients with untreated advanced GOA were included in the ancillary study of the PRODIGE 17-ACCORD 20 trial. CTCs were detected in the peripheral blood using the CellSearch system on day 0 (D0) and day 28 (D28). The prognostic value of CTCs at D0 and D28 was analysed by testing several thresholds. Results At baseline, median CTC count was 1 (range, 0–415). While CTCs ≥1, 2 or 3 at D0 were all significantly associated with worse overall survival (OS) and progression-free survival (PFS), CTCs ≥2 were the optimal threshold, on D0 or D28. CTCs ≥2 at D28 were also predictive of disease control. Taking into account both D0 and D28 CTC count defined 3 groups (low/low, high/low and low-high/high) with significantly different PFS (p = 0.0002) and OS (p = 0.003). Conclusion Quantification of CTCs at baseline and during treatment may be a useful prognostic tool in advanced GOA, as it is associated with worse PFS and OS. A threshold ≥2 CTCs seems to have the best discriminant value. Change in CTC count between baseline and D28 could help to tailor treatment to each individual patient.

AB - Background The identification of dynamic biomarkers in advanced gastric and oesogastric junction adenocarcinoma (GOA) could help to tailor strategies for each patient. Enumeration of circulating tumour cells (CTCs) is approved by the US Food and Drug Administration in breast, colon and prostate cancer but is not in advanced GOA. Our study aims to establish the optimal threshold and the clinical significance of CTC count in advanced GOA before and during treatment. Methods One hundred six patients with untreated advanced GOA were included in the ancillary study of the PRODIGE 17-ACCORD 20 trial. CTCs were detected in the peripheral blood using the CellSearch system on day 0 (D0) and day 28 (D28). The prognostic value of CTCs at D0 and D28 was analysed by testing several thresholds. Results At baseline, median CTC count was 1 (range, 0–415). While CTCs ≥1, 2 or 3 at D0 were all significantly associated with worse overall survival (OS) and progression-free survival (PFS), CTCs ≥2 were the optimal threshold, on D0 or D28. CTCs ≥2 at D28 were also predictive of disease control. Taking into account both D0 and D28 CTC count defined 3 groups (low/low, high/low and low-high/high) with significantly different PFS (p = 0.0002) and OS (p = 0.003). Conclusion Quantification of CTCs at baseline and during treatment may be a useful prognostic tool in advanced GOA, as it is associated with worse PFS and OS. A threshold ≥2 CTCs seems to have the best discriminant value. Change in CTC count between baseline and D28 could help to tailor treatment to each individual patient.

KW - Biomarkers

KW - Circulating tumour cells

KW - Clinical trial

KW - Prognosis

KW - Stomach neoplasms

UR - https://www.scopus.com/pages/publications/85018638569

U2 - 10.1016/j.ejca.2017.03.036

DO - 10.1016/j.ejca.2017.03.036

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 28456090

AN - SCOPUS:85018638569

SN - 0959-8049

VL - 79

SP - 15

EP - 22

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this